Bayer Stock at Crossroads: Strong Crop Science Quarter Battles $7.25 Billion Settlement Deadline and Pipeline Hopes

Bayer Q1: revenue up 4.1% to €13.4B, but litigation costs drain cash; net debt hits €32.5B. Key events: June 4 Roundup opt-out deadline and FDA priority review for Asundexian stroke drug.

A potent cocktail of operational strength and legal uncertainty continues to define Bayer’s trajectory. The German conglomerate delivered a solid first quarter fueled by its agriculture division, yet the stock remains mired near €37.8 a share — weighed down by the unresolved glyphosate liability and a debt pile that swelled to €32.5 billion. Two pivotal events now loom: a June 4 opt-out deadline for the company’s $7.25 billion Roundup class-action settlement, and a potential catalyst in the form of a US Food and Drug Administration priority review for its stroke drug Asundexian.

Legal Calendar Drives Near-Term Sentiment

The most immediate pressure point is legal. A preliminary $7.25 billion settlement agreement covering thousands of Roundup claims has been provisionally approved, but plaintiffs must decide by June 4 whether to exit the deal. That opt-out window is critical — if a significant number choose to walk away, Bayer could face renewed waves of litigation. Chief Executive Bill Anderson has vowed to materially reduce legal exposure this year irrespective of the Supreme Court’s upcoming decision in the "Durnell" case, which could preempt state-level failure-to-warn lawsuits if federal labeling rules prevail. A ruling is expected by the end of July, and a final court hearing on the settlement is scheduled for the same month.

FDA Priority Review Adds Pipeline Momentum

Amid the legal noise, Bayer’s pharmaceutical pipeline scored a notable win. The FDA accepted the company’s application for Asundexian and granted it priority review. The drug, a Factor XIa inhibitor, is designed to prevent secondary strokes in patients who have already suffered an ischemic stroke or transient ischemic attack. If approved, it would be the first-in-class therapy specifically authorized for secondary stroke prevention. The submission is based on the Phase III OCEANIC-STROKE trial, published in the New England Journal of Medicine. Separately, Bayer’s oncology candidate Hyrnuo also received an accelerated review designation from the FDA, broadening the late-stage pipeline’s depth.

Q1 Operating Strength — But Cash Bleeds

Bayer’s first-quarter numbers underscore the divergence between operations and financial health. Group revenue rose 4.1% on a currency-adjusted basis to €13.4 billion, while EBITDA before special items climbed 9.0% to €4.5 billion. Net profit more than doubled to €2.76 billion, driven by a strong performance from the Crop Science unit. Ag sales grew 6.8% currency-adjusted, lifted by corn seed gains and a licensing agreement in soybeans, alongside lower production costs from ongoing efficiency programs.

The dark side of the ledger was cash flow. Free cash flow came in at minus €2.3 billion, largely due to roughly €2.0 billion in payments tied to PCB and glyphosate litigation settlements. As a result, net financial debt rose to €32.5 billion — up 9% from the end of 2025. Management aims to slim that figure to €32.0 billion by year-end.

Analyst Upgrades Reflect Shifting Risk Assessment

The combination of a stronger-than-expected start to 2026 and progress on the pipeline prompted several analysts to raise their sights. DZ Bank lifted its fair value estimate from €44 to €51 and upgraded the stock from "Hold" to "Buy," citing the robust first quarter and diminished legal risks. Barclays raised its price target from €48 to €50 while maintaining an "Overweight" rating. The average target across 62 analysts now stands at €46.39, implying roughly 22% upside from current levels.

Bayer’s adjusted earnings per share improved 12.9% to €2.71 in the quarter, and the company reaffirmed full-year guidance: revenue of €44.5 billion to €46.5 billion, adjusted EPS of €4.10 to €4.60, and an adjusted operating result between €9.4 billion and €9.9 billion.

A Tug-of-War Between Valuation and Overhang

The share price reflects the tension. At €37.86, the stock trades about 23% below its 52-week high. It slipped to €37.81 on Tuesday, dipping below its 50-day moving average of €38.86 — a technical signal that caution still dominates the trading floor. The debt load, while manageable on an EBITDA basis, limits strategic flexibility and keeps financing costs elevated.

With the opt-out deadline on June 4 and the Supreme Court ruling anticipated in July, the next two months will set the tone for Bayer’s risk profile. The Asundexian priority review adds a promising element on the pipeline side, though the FDA’s final decision is not expected until late 2026. For now, the market is watching two clocks at once.